Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
June 17 2024 - 7:00AM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, announced Ian Taylor, Ph.D. has been promoted to
President of Research and Development and Angela Cacace, Ph.D. has
also been promoted and will succeed Dr. Taylor as Chief Scientific
Officer of the company. Dr. Taylor and Dr. Cacace will assume these
new roles effective immediately and report to John Houston, Ph.D.,
Chairperson, President and Chief Executive Officer.
"These promotions reflect the contributions of both Ian and
Angela to our success at Arvinas, as well as their crucial roles in
leading Arvinas through a new chapter in its evolution,” said John
Houston, Ph.D., Chairperson, President and Chief Executive Officer.
“Ian has been a driving force at Arvinas for the past eight years,
with his wealth of knowledge and passion for innovation, and we are
thrilled to announce his promotion to President of R&D. In his
new role, Ian will ensure our innovation efforts continue to push
the boundaries of what is possible, keeping Arvinas at the
forefront of our industry.”
Dr. Taylor joined Arvinas in 2016 as Vice President of
Pharmacology and Translational Medicine and has held positions of
increasing responsibility, including serving as Chief Scientific
Officer of the company since early 2019. Prior to Arvinas, Dr.
Taylor had long tenures at Bayer and Pfizer, where he held
leadership roles in Oncology Research and Development,
respectively. As President of R&D, Dr. Taylor will provide
strategic input across the company’s broad pipeline, from early
research efforts to multiple development programs in oncology and
neuroscience. Dr. Taylor will continue to be an important
connection to outside stakeholders, including thought leaders,
strategic partners, and investors, and will also chair the
Company’s Scientific Advisory Board, with whom he’s worked since
joining Arvinas.
“I am honored to take on this new role at Arvinas,” said Dr.
Taylor. “I am very proud of what we have already accomplished as a
company and have an unwavering conviction that the future of
Arvinas is even brighter, given the incredible strength of our
clinical portfolio and the research pipeline that we’ve built. I
look forward to continuing to play a strategic role, along with
John and the leadership team, to bring our PROTAC® protein
degraders to patients. Angela is ideally suited to be our next
Chief Scientific Officer and she will step in to that position
seamlessly.”
“Angela has been instrumental in our success and I am excited we
are promoting her to Chief Scientific Officer,” continued Dr.
Houston. “Her visionary approach over the past six years at Arvinas
helped to build our neuroscience and platform capabilities and she
was a driving force in our nomination of ARV-102, Arvinas’ first
investigational PROTAC degrader for neurodegeneration, into
clinical development. With her deep scientific and technical
expertise in cancer biology and cancer drug discovery, I am
confident that as CSO, Angela will continue to drive our research
pipeline forward.”
Dr. Cacace joined Arvinas in 2018 as Vice President of
Neuroscience and Platform Biology, bringing over two decades of
drug discovery experience in neuroscience and oncology research
across modalities. She most recently served as Senior Vice
President, Neuroscience and Platform Biology. Her prior experience
at Pfizer focused on oncology antibody drug discovery efforts to
deliver an anti-angiogenic clinical candidate. While at
Bristol-Myers Squibb, in positions of increasing responsibility in
research, and as head of biology at Fulcrum Therapeutics, she built
innovative pipelines, grew talented scientific teams, delivered
multiple clinical candidates, and guided the development of
translational biomarkers to enable clinical development programs.
Over the past six years, together with the Arvinas team, Dr. Cacace
has led the continuous evolution of Arvinas’ powerful PROTAC®
Discovery Engine to employ new E3 ligases and cross the blood-brain
barrier for multiple neurologic disease targets, including the
delivery of PROTAC® LRRK2 degrader ARV-102 into ongoing clinical
trials.
“I am thrilled to take on this role at Arvinas during this
crucial stage in our company's journey,” said Dr. Cacace. “I have
long been committed to fostering a collaborative and innovative
environment that advances our pipeline from early discovery through
clinical development. By integrating our scientific efforts with
our overall business strategy, we aim to accelerate the translation
of our targeted protein degradation research into meaningful
clinical trials and potentially impactful treatments. Patients are
at the heart of everything we do, and we will continue to push the
boundaries of science with urgency and purpose.”
About ArvinasArvinas (Nasdaq: ARVN) is a
clinical-stage biotechnology company dedicated to improving the
lives of patients suffering from debilitating and life-threatening
diseases. Through its PROTAC® (PROteolysis Targeting Chimera)
protein degrader platform, the Company is pioneering the
development of protein degradation therapies designed to harness
the body’s natural protein disposal system to selectively and
efficiently degrade and remove disease-causing proteins. Arvinas is
currently progressing multiple investigational drugs through
clinical development programs, including vepdegestrant, targeting
estrogen receptor for patients with locally advanced or metastatic
ER+/HER2- breast cancer; ARV-102, targeting LRRK2 for
neurodegenerative disorders; and ARV-393, targeting BCL6 for
relapsed/refractory non-Hodgkin Lymphoma. Arvinas is headquartered
in New Haven, Connecticut. For more information about Arvinas,
visit us on www.arvinas.com, which does not form part of this
release, and connect with us on LinkedIn and X.
Arvinas Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995 that involve substantial risks and
uncertainties, including statements regarding Arvinas’ ability to
bring its technology to patients, including its ability to
accelerate the translation of its targeted protein degradation
research into meaningful clinical trials and impactful treatment;
the potential therapeutic benefits of the product candidates in
Arvinas’ PROTAC® protein degrader pipeline; the future of Arvinas
based on strength of its clinical portfolio and research pipeline;
and the impact the enumerated promotions may have on the company.
The words “believe,” “expect,” “may,” “plan,” “potential,” “will,”
“continue,” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Arvinas may not
actually achieve the plans, intentions or expectations disclosed in
these forward-looking statements, and you should not place undue
reliance on such forward-looking statements. Actual results or
events could differ materially from the plans, intentions and
expectations disclosed in the forward-looking statements made as a
result of various risks and uncertainties, including but not
limited to: Arvinas’ approach to the discovery and development of
product candidates based on its PROTAC technology platform is
unproven, which makes it difficult to predict the time, cost of
development and likelihood of successfully developing any products;
Arvinas’ ability to protect its intellectual property position;
whether cash and cash equivalent resources will be sufficient to
fund Arvinas’ foreseeable and unforeseeable operating expenses and
capital expenditure requirements; and other important factors
discussed in the “Risk Factors” section of the company’s Annual
Report on Form 10-K for the year ended December 31, 2023, and
subsequent other reports on file with the U.S. Securities and
Exchange Commission. The forward-looking statements contained in
this press release reflect current views with respect to future
events, and Arvinas assumes no obligation to update any
forward-looking statements except as required by applicable law.
These forward-looking statements should not be relied upon as
representing Arvinas’ views as of any date after the date of this
release.
Contacts
Investor Contact:Jeff Boyle, Arvinas Investor
Relations+1 (347) 247-5089Jeff.Boyle@arvinas.com
Media Contact:Kathleen Murphy, Arvinas
Communications+1 (760) 622-3771Kathleen.Murphy@arvinas.com
Photos accompanying this announcement are available
at:https://www.globenewswire.com/NewsRoom/AttachmentNg/4b3b7113-9acc-4f80-aea9-1930844e31d8
https://www.globenewswire.com/NewsRoom/AttachmentNg/aeafe7ea-ecdf-48d2-a74f-a873fc25ed9a
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Oct 2023 to Oct 2024